This is a press release test
Why do people diagnosed with blood cancer often leave with less knowledge of their condition compared to other cancers? We're tackling that question and outlining what we can do to raise the profile of blood cancer as a health condition
Example press release
"People with blood cancer should continue to take up COVID-19 vaccines when offered through seasonal programmes as it protects them from serious illness and hospitalisation.
"Like all drugs, vaccines have potential side effects but the current evidence indicates that for people with immunosuppression caused by blood cancer, including leukaemia, lymphoma, myeloma, MDS and MPN, or its treatments, the additional protection provided by COVID-19 vaccines is very likely to outweigh the small risk of side effects or complications. The QResearch study found no evidence that people with blood cancer were at an increased risk of side effects after vaccination compared with the general population.
"While we know that some people with weakened immune systems have historically had a reduced immune response to COVID-19 vaccines, the MELODY study showed that an increasing number of vaccine doses contributed to higher rates of COVID-19 antibody presence in people with weakened immune systems. People with the blood cancer lymphoma were included in this study. We also know that COVID-19 vaccines can induce protective T-cell responses even in patients who don’t make antibodies effectively.
"The QResearch study also showed that continuing to have doses of COVID-19 vaccines is important for people with blood cancer to maintain their immunity. Repeat vaccination is important because COVID-19 vaccines are updated seasonally so that they are more effective against current or recently circulating variants of the virus, much like flu vaccines.
Press release in Welsh
“Dylai pobl â chanser y gwaed barhau i dderbyn brechlynnau COVID-19 pan gânt eu cynnig trwy raglenni tymhorol gan ei fod yn eu hamddiffyn rhag salwch difrifol a mynd i'r ysbyty.
“Fel pob cyffur, mae gan frechlynnau sgil-effeithiau posibl ond mae’r dystiolaeth bresennol yn dangos mai’r amddiffyniad ychwanegol a ddarperir gan frechlynnau COVID-19 yw’r amddiffyniad ychwanegol a ddarperir gan frechlynnau COVID-19 i bobl ag imiwnedd a achosir gan ganser y gwaed, gan gynnwys lewcemia, lymffoma, myeloma, MDS ac MPN. yn debygol iawn o orbwyso'r risg fach o sgîl-effeithiau neu gymhlethdodau Ni chanfu astudiaeth QResearch unrhyw dystiolaeth bod pobl â chanser y gwaed mewn mwy o berygl o sgîl-effeithiau ar ôl cael eu brechu o gymharu â'r boblogaeth gyffredinol.
“Er ein bod yn gwybod bod rhai pobl â systemau imiwnedd gwan yn hanesyddol wedi cael ymateb imiwn llai i frechlynnau COVID-19, dangosodd astudiaeth MELODY fod nifer cynyddol o ddosau brechlyn wedi cyfrannu at gyfraddau uwch o bresenoldeb gwrthgyrff COVID-19 mewn pobl ag imiwnedd gwan. Cynhwyswyd pobl â lymffoma canser y gwaed yn yr astudiaeth hon Rydym hefyd yn gwybod y gall brechlynnau COVID-19 ysgogi ymatebion amddiffynnol celloedd T hyd yn oed mewn cleifion nad ydynt yn gwneud gwrthgyrff yn effeithiol.
"Dangosodd astudiaeth QResearch hefyd fod parhau i gael dosau o frechlynnau COVID-19 yn bwysig i bobl â chanser y gwaed gynnal eu himiwnedd. Mae ail-frechu yn bwysig oherwydd bod brechlynnau COVID-19 yn cael eu diweddaru'n dymhorol fel eu bod yn fwy effeithiol yn erbyn y presennol neu'n ddiweddar. amrywiadau sy'n cylchredeg o'r firws, yn debyg iawn i frechlynnau ffliw.